| Literature DB >> 33808492 |
M Sai Bhargava Reddy1, Deepalekshmi Ponnamma2, Rajan Choudhary3,4,5, Kishor Kumar Sadasivuni2.
Abstract
Tissue engineering (TE) and regenerative medicine integrate information and technology from various fields to restore/replace tissues and damaged organs for medical treatments. To achieve this, scaffolds act as delivery vectors or as cellular systems for drugs and cells; thereby, cellular material is able to colonize host cells sufficiently to meet up the requirements of regeneration and repair. This process is multi-stage and requires the development of various components to create the desired neo-tissue or organ. In several current TE strategies, biomaterials are essential components. While several polymers are established for their use as biomaterials, careful consideration of the cellular environment and interactions needed is required in selecting a polymer for a given application. Depending on this, scaffold materials can be of natural or synthetic origin, degradable or nondegradable. In this review, an overview of various natural and synthetic polymers and their possible composite scaffolds with their physicochemical properties including biocompatibility, biodegradability, morphology, mechanical strength, pore size, and porosity are discussed. The scaffolds fabrication techniques and a few commercially available biopolymers are also tabulated.Entities:
Keywords: biodegradability; natural biopolymer; scaffolds; synthetic biopolymer; tissue engineering
Year: 2021 PMID: 33808492 PMCID: PMC8037451 DOI: 10.3390/polym13071105
Source DB: PubMed Journal: Polymers (Basel) ISSN: 2073-4360 Impact factor: 4.329
Figure 1The essential variables involved in scaffold design for TE.
Figure 2Natural and synthetic polymers were rearranged based on bio vs non-bio and biodegradable vs nonbiodegradable characteristics, where PHB: polyhydroxybutyrate; PLA: polylactic acid; PCL: polycaprolactone; PGA: poly(glycolic acid); PVA: poly(vinyl alcohol); PEA: poly(ethylene adipate); PES: polyethersulfone; PBS: polybutylene succinate; PET: polyethylene terephthalate; PE: polyethylene; PP: polypropylene; PVC: polyvinyl chloride; PC: polycarbonate; PS: polystyrene; PA: polyamide; and PEF: polyethylene furanoate.
Comprehensive analysis of naturally occurring and synthetic biopolymers along with their advantages and disadvantages.
| Polymer | Structure | Desirable Properties and | Disadvantages | Ref | ||
|---|---|---|---|---|---|---|
|
|
|
| Triple helical structure held together by hydrogen bonds. Major amino acid |
Favorable for cell adhesion, proliferation, differentiation, and ECM secretion. Excellent biocompatibility. Biodegradability. Low toxicity. Rough surface morphology. Low immunogenicity. Weak antigenicity. |
Low mechanical strength. Difficult disinfection. The deformation and contraction of collagen-based scaffolds have restricted their use in load-bearing tissues. Poor stability in an aqueous environment. Potential for antigenicity through telopeptides. | [ |
|
|
Consists of short amino acid side chains that assemble into β-sheet structures. |
SFs are sturdy, lightweight, and have exceptional strength and elasticity. Osteoconductivity. Biocompatible. Deliver good support for cell adhesion and proliferation without initiating cell toxicity. Promote cell migration and vascularization. Moderately degradable. Thermostable (up to ∼250 °C). Commonly employed as a cell carrier for cell seeding on scaffolds. |
Prolonged presence of silk may induce degradation, which releases certain residues or degraded products that may prompt the immune response. | [ | ||
|
|
Fibrinogen: Dimer consisting of three pairs of polypeptide chains (Aα, Bβ, and γ) |
Biocompatibility. High affinity for biological surfaces and molecules. Promotes cellular interactions. Variety of cell-adhesive/binding properties. Nonimmunogenicity. |
Low mechanical strength. Quick rate of degradation. | [ | ||
|
| Contains glycine residues, proline, and 4-hydroxyproline |
Better infiltration, adhesion, spreading, and proliferation of cells on resulting scaffolds. Good stability at high temperature in a broad range of pH. Biodegradability. Osteoconductivity. Non-immunogenic. Low antigenicity. |
Bioactivity is questionable in higher-order gelatin structures in scaffolds. Low stability in physiological conditions. | [ | ||
|
|
It is a cysteine-rich fibrous protein that associates with intermediate filaments (IFs) forming the bulk of the cytoskeleton and epidermal appendageal structures |
Facilitates cell adhesion and proliferation. Unique chemistry afforded by high sulfur content. Propensity for self-assembly. Intrinsic cellular recognition. Intrinsic biological activity. Cytocompatibility. Gradual degradation. |
Poor mechanical properties. Quick loss of mechanical integrity. | [ | ||
|
|
|
Comprised of carbohydrates. The structure consists of two types of alpha glucan which are amylose and amylopectin. |
Biocompatible. Thermoplastic behavior. Non-cytotoxic. Guides various developmental stages of cells. Hydrophilicity. Good substrate for cell adhesion. Good biodegradation period. |
Very high water uptake. Low mechanical strength. Unstable for long-term application. Chemical modifications may lead to toxic byproducts and reduce the rate of degradation. | [ | |
|
|
Chitin: N-acetyl glucosamine and N-glucosamine monomers Chitosan: N-deacetylated derivative of chitin |
Accelerates tissue repair. Prevents formation of scar tissue. Promotes cell adhesion. Non-toxic and non-allergenic. Bioactivity. Anti-inflammatory. Osteoconductivity. Hemostatic potential. Scaffolds could be used for a longer period. Chitosan-based scaffolds can immobilize growth factors. |
Poor mechanical strength and stability. High viscosity and low solubility at neutral pH. Rapid in vivo degradation rate. | [ | ||
|
|
Contains repeating units of agarobiose (a disaccharide of D-galactose and 3,6-anhydro-l-galactopyranose). |
Excellent biocompatibility. Thermo-reversible gelation behavior. Exceptional electroresponsiveness. Suitable medium for cell encapsulation. Non-immunogenic. |
Low cell adhesion. Nondegradability due to the absence of an appropriate enzyme in the body. | [ | ||
|
|
Made up of mannuronate and gluronate monomers. Different block configurations give rise to different materials properties. Mainly made up of carboxyl groups. |
Mimicking function of the extracellular matrix of body tissue. Thickening/gel-forming agent. Biocompatibility. Cytocompatibility. Biodegradability. Bioabsorbable. Hydrophilicity. |
Difficult to sterilize. Low cell adhesion. Poor mechanical characteristics. | [ | ||
|
|
Polysaccharides are formed by many D-glucose units connected by glycosidic bonds. |
Stable matrix for tissue engineering applications. Better mechanical strength. Hydrophilicity. Biocompatibility. Cytocompatibility. Bioactivity. |
Cellulose in the human organism behaves as a nondegradable or very slowly degradable material. | [ | ||
|
|
It is a linear, anionic, non-sulfated glycosaminoglycan with a structure composed of repeating disaccharides units: β-1,4-D-glucuronic acid and β-1,3-N-acetyl-D-glucosamide. |
Encapsulation capability. Cell activity. HA scaffolds are frequently used in the case of both hard and soft tissue regeneration. Nonimmunogenic. Nonantigenic. Biocompatibility. Osteocompatibility. |
Brittle; mechanical properties need fine-tuning via chemical modification. Low biodegradability in the crystalline phase. | [ | ||
|
|
Consist of repeating disaccharides linked by glycosidic bonds creating individual complex structures. |
Biocompatibility. Anticoagulant activity. Antithrombotic activity. Anti-inflammatory. Have multiple regulatory functions, e.g., in the anticoagulation of blood, inhibition of tumor growth, and metastasis. Control the inflammatory processes. |
Very fast degradation. Potential risk of contamination with infectious agents. | [ | ||
|
|
|
Aliphatic semicrystalline polyester. |
Controls cell proliferation and angiogenesis. Slow degradation rate (lower than that of PLA and PLGA). Non-toxic. Cytocompatibility. Good mechanical properties. Degraded by hydrolysis or bulk erosion. |
Low bioactivity. Hydrophobicity of PCL is another major issue that hinders wound healing application. Some problems related to withstanding mechanical loads. | [ | |
|
|
Highly crystalline. |
Biocompatible. Cytocompatibility. Thermal stability. Excellent mechanical strength. Good degradation rate. Nontoxic degradation products. |
PLA-based materials suffer from the lack of ideal surface chemistry that could aid cell adhesion and proliferation. Brittleness. Poor thermal stability. Hydrophobicity. | [ | ||
|
|
The copolymer of hydrophobic PLA and hydrophilic PGA. |
Excellent cell adhesion and proliferation. Good mechanical properties. Features faster degradation than either PGA or PLA. Wide range of degradation rates. |
Poor osteoconductivity. May develop biocompatibility problems. | [ | ||
|
|
Linear highly crystalline aliphatic polyester. |
Biocompatible. High tensile modulus. High melting point. Undergoes bulk degradation. Hydrophilicity. |
High sensitivity to hydrolysis. Difficult to obtain porous PGA scaffolds without toxic solvents. | [ | ||
|
|
It is a homopolymer having a stereoregular structure with high crystallinity. Naturally occurring b-hydroxy acid. |
Non-toxic. Biostable. Biocompatible. Advantages over PLA and PGA. Slow rate of degradation. Can be obtained naturally. |
Inherent brittleness and rigidity. Thermal instability during melt processing impedes its commercial application. | [ | ||
|
|
Linear and unsaturated copolyester based on fumaric acid. |
Biocompatibility. Crosslinked PPF matrices have high mechanical strength. PPF degrades in the presence of water into propylene glycol and fumaric acid, the degradation products that are easily cleared from the human body by normal metabolic processes. Non-toxic. |
It is a viscous liquid at room temperature (21 °C), making the handling of the polymer somewhat cumbersome | [ | ||
|
|
Synthesized using ring-opening polymerization of ethylene oxide. |
Non-ionic. Biocompatible. Elasticity. Bioadhesive. Mucoadhesive. Hinders protein adsorption. Hydrophilic. PEG as a blank template can be modified to different moieties to pass different requirements of a skin substitute like cell adhesion, short-term degradation, and minimum inflammation. Non-immunogenic. | Lacks cell-interactive character due to Nonreactive, creates insoluble networks. | [ | ||
|
|
Urethane groups are the major repeating units. Synthesized by reactions of di- or polyisocyanates (hard segments) with di- or polyols (soft segments) via the catalyzed polymerization process. |
Bio- and hemocompatibility. Nontoxic. Biodegradable. Non-allergenic. Non-sensitizing. Excellent mechanical properties. High flexural endurance and fatigue resistance. |
PUs are less compatible with blood and found unsuitable for in vivo drug delivery application. Limited stability in vivo. | [ | ||
|
|
Semicrystalline polyhydroxy polymer. Prepared via hydrolysis of poly(vinyl acetate). |
Biocompatible. Nontoxic. Noncarcinogenic. Displays a reduced protein-binding tendency, relatively higher elasticity and water content; a highly hydrated water-soluble synthetic polymer. Has relatively similar tensile strength to human articular cartilages. Good lubrication. |
Lack of cell-adhesive property. Less ingrowth of bone cells. | [ | ||
|
|
Product of alternating copolymerization of propylene oxide and CO2. Amorphous. |
Biodegradable amorphous polymer because of the aliphatic polycarbonate ester structure on its backbone. No inflammatory response. Thermoplastic behavior. Biocompatibility. Impact resistance. | PPC has shortcomings such as viscous Poor thermal and processing properties. Cell attachment to PPC is very limited due to its highly hydrophobic nature. | [ | ||
Comprehensive analysis of natural biopolymer blends (composites) along with their fabrication route, properties, biological assessment, and characteristics.
| Natural–Natural Biopolymer Composite Scaffold Material | Fabrication Method | Properties Considered | Biological Assessment | Characteristics | Scaffold Application | Ref. |
|---|---|---|---|---|---|---|
| Collagen | Freeze-drying |
Porosity: 98.8%. Young’s modulus: ~240 KPa (after 8 weeks). |
Cell seeding efficiency: 93.8 ± 2.0%. In vivo implantation. Histological and immunohistochemical evaluations. |
The highest stimulating effect was seen on gene expression and cartilaginous matrix protein production and also on cartilage regeneration. The findings of vivo implantation showed that the pore size had no apparent effect on the proliferation of cells. | Cartilage regeneration | [ |
| Collagen/gelatin/chitosan (40–20–40%) | Freeze-drying |
Porosity: 61.34% ± 2.53%. Density: 0.0522 g/cm3. Swelling: 34.8% (in PBS). Stress: 4 MPa. |
ABTS (2,2′-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid)) % of inhibition = 3.0268. Maximum zone of inhibition: 12 mm ( |
Wound-healing properties. Obviates the need to remove the material later or leave materials in the body. The efficiency of the antimicrobial activity decreases over time. | Tissue engineering | [ |
| Collagen–chitosan (7:3) | Lyophilization | Swelling: ~8%. In vitro degradation: > 15% |
Protein adsorption: 0.65 (optical density (OD562nm)). |
Higher protein absorption. Decrement in the rate of degradation compared to a pristine polymer. | Tissue regeneration | [ |
| Cellulose–collagen (5:1) | Freeze-drying |
Water uptake: 400%. Contraction: ~3%. |
Cell proliferation: 9 × 104 (number of cells in three days). Percentage of neovessel-occupied area: ~4%. Percentage of blood vessel-occupied area (number of cells/mm2): 4.06 ± 0.8%. |
Excellent physical stability. Provides 3D environment for good cell retention and proliferation. Provides microenvironment for induction of osteogenic differentiation of mesenchymal stem cells extracted from umbilical cord blood (UCB-MSCs). Collagen’s low mechanical properties are a weak point. | Bone tissue engineering | [ |
| Silk fibrils/chitosan (3:4) | Freeze-drying |
Tensile strength: 40.1 ± 1.9 MPa. Compressive modulus and strength at 60% strain in dry state: 81.7 ± 6.2 kPa and 78.5 ± 3.6 kPa. |
/ |
Improved thermal stability and mechanical strength. Due to the addition of the silk nanofibrils SNF, the maximum thermal decomposition temperature is increased. The ECM composition is imitated by SNF/CS nanocomposites and thus offers choices for the creation of novel biomaterials. | Would dressing, tissue engineering scaffolds, flexible biodevices | [ |
| Chitosan/SF (7:3) | Lyophilization |
Elastic modulus: 5.3 ± 0.2 MPa. Tensile strength: 3.1 ± 0.7 MPa. Elongation at break: 56 ± 7.4%. Suture retention strength: 1.96 ± 0.25 N. Swelling index: 348 ± 39%. |
Cell isolation and culture. Cell adhesion and proliferation. Immunohisto-chemistry. |
Mechanical strength, oxygen, and nutrient permeability prevent fibrous scar tissue invasion. | Nerve regeneration, cartilage regeneration | [ |
| SF (7 w/v%)/chitosan–gelatin (1:2) cross-linked with methanol and glutaraldehyde | Freeze-drying |
Pore size: 175 ± 15 µm. Porosity: 78%. Tensile strength: 11 ± 0.26 KPa. Young’s modulus: 40 ± 3.8 KPa. Breaking strain: 27.5 ± 2.02%. Contact angle (°): 58 ± 7. Swelling index: ~90%. Degradation: ~55% (four weeks). |
Absorbance (490 nm): 1.1 (six days). Histological assessment. |
Mechanical features similar to those of the native soft tissues were seen in the formed scaffolds. High degradation rate. The mechanical strength and degradation rate improved by the addition of silk fibroin to the composites. Compared with silk fibroin alone, the composite scaffolds have increased endothelial cell attachment and growth. | Tissue engineering | [ |
| Oxidized alginate/gelatin/SF (13:17:10 w/v%) | Electrospinning |
Pore size: 412.58 ± 86.2 µm. Porosity: 80.9 ± 3.1%. Water uptake: > 100%. Degradation: ~50% (four weeks). Young’s modulus: 1.84 MPa. |
Cell viability and proliferation: ~0.7 for seven days (OD, 562 nm). |
Non-toxic and supports AMSC (adipose-derived mesenchymal stem cells) proliferation. Higher thermal stability. | Regenerative medicine, skin tissue engineering | [ |
| Collagen–HA (15 wt.%) | Freeze-drying |
Relative density: 0.0121 ± 0.0008. Porosity: ~85%. Degradation rate: 13.3% (seven days). Young’s modulus: 6.73 ± 0.41 KPa. Collapse plateau modulus: 3.17 ± 0.36 KPa. Elastic collapse stress: 625 ± 29 Pa. Elastic collapse strain: 0.10 ± 0.01. |
Cell culture. Immunohisto-chemistry. |
Collagen–HA scaffolds that favor the differentiation of neural stem cells into neuronal cells in vitro in tandem with some mechanical behaviour of brain tissue. | Brain tissue engineering | [ |
| Alginate/cellulose nanocrystals–chitosan–gelatin | Layer-by-layer assembly and then freeze-drying |
Porosity: 77.4%. Compressive strength: ~0.28 MPa. Degradation rate: ~23% (two weeks). |
Cell proliferation: 3.8 for five days (OD, 562 nm). Relative ALP (alkaline phosphatase) activity: 1.5 after six days of incubation. |
A strong 3D architecture with a well-defined porous structure improves compressive strength and controlled biodegradation. | Bone tissue engineering | [ |
Comprehensive analysis of natural–synthetic biopolymer blends (composites) along with their fabrication route, properties, biological assessment, and characteristics.
| Natural–Synthetic Biopolymer Composite Scaffold Material | Fabrication Method | Properties Considered | Biological Assessment | Characteristics | Scaffold Application | Ref. |
|---|---|---|---|---|---|---|
| PCL/collagen | Electrospinning |
Tensile strength: 0.9 MPa (explanted in one month). Graft patency and geometry, structural integrity. |
Cell culture, histology, cell adherence, and resistance to platelet adherence. |
Maintains a high degree of patency and structural integrity in vivo without eliciting abnormal inflammatory response over one month. Capable of promoting endothelial and muscle cell growth under conditions of pulsatile flow. Issues such as immune response, scaffold cell remodeling, and in vivo development of thrombosis have not been described. | Vascular tissue engineering | [ |
| Chitosan/PLLA/pectin (50:25:25) | Freeze drying |
Avg. pore size: 49–164 μm. Porosity: 81 ± 1.97%. Swelling ratio: 1.6 (36 h). Degradation: ~38% (28 days). |
Cell proliferation: 0.7 (seven days). Hemocompatibility: 1.97% hemolysis. Biopsy collection and chondrocytes culture. Cytocompatibility assay. Cell viability analysis. Histopathological. Immunofluorescence studies. |
Displays an increase in compressive strength, controlled swelling property, lower degradation behavior, and hemocompatibility according to the polymeric proportion. The in vivo study accompanied by histological analysis demonstrated the neo-cartilage tissue regeneration potential of the cell–scaffold construct. | Neo-cartilage tissue regeneration, surgical manipulation | [ |
| PLA/chitosan | Fused filament fabrication (3D printing) |
Tensile strength: 44.56 MPa. Compression strength: 47.15 MPa. Flexural strength: 156.96 MPa. |
/ |
The established scaffold has a considerably higher flexural strength than compression strength and tensile strength, which makes the scaffold ideal for dynamic movements. Lower tensile strength and compression strength. PLA/chitosan scaffolds have a lower strength than PLA scaffolds. | Clinical purposes | [ |
| Alginate-coated PLLA/PLGA (95:5, w/w) | Lyophilization |
Pore size: 39 ± 24 μm. Porosity: 60–65%. Compressive modulus: 1415 ± 153 kPa. Compressive strength: 128 ± 18 kPa. Degradation: 40% (eight weeks). |
Cell proliferation: ~25 × 104 (number of cells in 15 days). Cell morphology. |
Cell proliferation rate is low on alginate-coated scaffolds. Cells are also shown to become more branched in the presence of alginate. | Designing engineered tissues | [ |
| PLLA/gelatin (6%)/osteo (1.5%) | Electrospinning and 3D printing (FDM: Fused deposition modeling) |
Tensile strength: 17.7 ± 1.8 MPa. Porosity: 44.1%. |
Bioactivity. Cell culture. Cytotoxicity. Proliferation. |
The presence of gelatin and an osteogenic drug on the surface of 3D-printed PLLA scaffolds offers mineralization of the samples proving its bioactivity. | Nasal cartilages and subchondral bone reconstruction | [ |
| PLLA/PCL/HA | Electrospinning associated with electrospray |
Thickness: 16 ± 4 µm. Young’s modulus: 2.99 ± 0.63 MPa. Tensile strength: 11.32 ± 1.94 MPa. Elongation at break: 131.83 ± 6.82 %. |
Metabolic activity of MC3T3-E1 cells/area: ~1500 (RFU/mm2) (where RFU: relative fluorescence units). Total number of colony-forming units (CFU) per mL of |
Enhancement of mechanical strength. The adhesion and proliferation of osteoblast cells and the fiber alignment are induced to increase the metabolic activity of the cells. | Tissue engineering | [ |
| CS/PVA/ methylcellulose | Combination of film casting and lyophilization methods |
Porosity: 88%. Young’s modulus: 119.3 ± 0.4 MPa. Tensile strength: 8.40 ± 0.3 MPa. Elongation at break: 8 ± 0.9 %. Degradation: 39 ± 2.0%. Swelling degree: 71 ± 3.6%. |
Bacteriostatic rate: 81.2 ± 3.9 % ( Cell proliferation assay of L929 cells: ~1.6 (seven days). |
The compatibility between CS and PVA has improved by adding MC. Along with the high swelling rate, the mechanical characteristics of these scaffolds are greatly improved. The biocompatibility test showed that there is no cytotoxicity in the various MC scaffolds. | Drug delivery vehicles and skin tissue engineering | [ |
| PCL/PPy | Electrospinning (ES) |
Young’s modulus:10.50 MPa. Tensile strength:15.26 MPa. Strain at break: 320.07%. Contact angle: 93.40 ± 0.36. Conductivity: 15.60 × 10−7 (S/m). |
Cell viability with ES: 1.95 (OD, 450 nm) (seven days). ALP activity with ES: 8.5 (mM) (14 days). ARS (Alizarin red S) staining with ES: 2.35 (21 days). |
In electric stimulation conditions, PCL/PPy show improved MC3T3-E1 cellular adhesion, proliferation, and differentiation. Increased simulated body fluid (SBF)-biomineralization has been shown for PCL/PPy conductive scaffolds. | Bone tissue engineering | [ |
| Chitosan(CS)/PCL(P)/gelatin(G) | Electrospinning followed by freeze-drying |
Pore size: 8.8 ± 1.4 μm. Porosity: 47%. Swelling ratio: 1270 ± 16%. Contact angle: 46.9 ± 2.0°. Maximum stress: 0.372 ± 0.029 MPa. Strain at failure: 80%. Young’s modulus: 0.4 MPa. Degradation rate: 20% (three months). |
Cell biocompatibility analysis. Cell viability analysis. Collagen secretion measurement. Cell attachment analysis. Hemostatic effect in vitro. Biodegradability analysis in vivo. Cell infiltration analysis. |
The composite scaffolds had good blood coagulation abilities because of the hemostatic properties of CS and the porous structure. Filaments and tiny pores in composite CS–PG scaffolds may serve as effective barriers and prevent cell infiltration. | Periodontal regeneration | [ |
| PCL/PVP (polyvinylpyrrolidone) | E-jet 3D printing |
Jetting morphology. Printed structures features. |
Cell viability: 95 ± 3.5% (five days). Normalized cell density: 500 (five days). |
The composite PCL/PVP scaffolds are printed with the controllable diameter of the filament (~10 μm) that is close to living cells. Experiments in cell culture found that printed scaffolds have excellent biocompatibility and support in vitro cell proliferation. | Cartilage regeneration | [ |
| PLA/regenerated cellulose (RC) | Electrospinning and freeze-drying techniques |
Porosity: 96.3 ± 0.2%. Density: 32.4 ± 0.2 mg/cm3. Water absorption capacity: 3500%. Youngs modulus: 54.9 kPa. Compressive stress at 80% strain: 120 KPa. Degradation: 14.66% (56 days). |
In vitro biomineralization. |
Increased hydrophilicity and biological activity. The properties of high water absorption, hierarchical cellular structure, and rapid recovery from 80 percent strain are presented by PLA/RC nanofiber-reconfigured scaffolds. | Bone tissue engineering | [ |
| PLA/cellulose nanocrystals | Electrospinning |
Modulus: 1.32 MPa. Toughness: 2.07 mJ/m3. |
Cell viability: ~240 % (five days). Mineralization (A562): 0.3 (14 days). Cell morphology. Real-time PCR analysis. In vivo study and histological analysis of bone regeneration. |
Outstanding adhesion and mineralisation. Enhanced osteogenesis by manufacturing electrospun scaffolds. Improved bone regeneration in a scaffold-treated group. | Bone tissue engineering | [ |
| PCL/polyaniline (0.1 wt.%) | Screw-assisted extrusion-based 3D printing |
Pore size: 305.9 ± 35.5 μm. Porosity: 48.16 ± 1.071%. Contact angle: 83°. Compressive Young’s modulus: 68.35 ± 5.15 MPa. Compressive strength: 6.45 ± 0.16 MPa. Conductivity: 2.46 ± 0.65 × 10−4 S/cm. |
Cell viability: 88% (one day). |
The highest cell viability with cytocompatibility in cell culture has been demonstrated for up to 21 days. | Bone tissue engineering | [ |
| PBS/cellulose nanocrystals (5 wt.%) | Two-step depressurization in a supercritical carbon dioxide (Sc-CO2) foaming process |
Compressive strength: 2.76 MPa. Contact angle: 71.7°. Porosity: 95.2%. Degradation rate: 20.5% (six weeks). |
Cell viability (% of a living cell): 98.05 (seven days). Cell proliferation (OD values): ~1.0 (seven days). |
The strong in vitro biocompatibility has been demonstrated and can provide effective cell attachment and proliferation environment. | Tissue engineering | [ |
Figure 3The essential variables that define the scaffold’s biocompatibility.
Figure 4Biodegradation mechanisms of natural and synthetic polymers.
Degradation mechanism of biodegradable polymer scaffolds.
| Scaffold Material | Degradation Mechanism | Degradation Duration (Weeks) | Degradation Rate (%) | Solvent | Application | Ref. |
|---|---|---|---|---|---|---|
| Alginate | Enzymatic | 4 | >70 | DMEM + FBS | Bone and cartilage tissue substitutes | [ |
| Gelatin | Hydrolysis, dissolving, transformation, and enzyme-catalyzed decomposition | 2.5 | 94.9 | Lysozyme | Cartilage cells | [ |
| Chitosan/gelatin | Enzymatic | 4 | 28 ± 3.5 | PBS | Tissue engineering | [ |
| Chitosan | Enzymatic | 4 | ∼60 | Lysozyme | Cartilage regeneration | [ |
| Silk fibroin/chitosan | 50 | |||||
| Silk fibroin/hyaluronic acid | Enzymatic | 3 | ∼47 | Collagenase IA solution | Soft tissue engineering | [ |
| Silk fibroin | ∼72 | |||||
| Chitosan/gelatin | Enzymatic | 3 | 50–60 | PBS with lysozyme | Biomedical applications | [ |
| Collagen | Enzymatic | 2 | 71 | PBS | Tissue engineering | [ |
| Collagen/PLLA | Hydrolysis and enzymatic | 5 | ||||
| Starch/PVA | Hydrolytic | 4 | 27.1 | Simulated body fluid (SBF) | Bone tissue | [ |
| Chitosan/PVP–PLGA | Hydrolytic | 4–6 | 100 | PBS | Allergic rhinitis and chronic sinusitis | [ |
| PLA | Enzymatic | 32 | 80 | Simulated body fluid (SBF) | Tissue engineering | [ |
| PGA | Hydrolytic | 1–6 | 50 | PBS | Tissue-engineered vascular grafts | [ |
| PCL | Hydrolytic | 24 | 7 | PBS | Drug delivery and tissue engineering | [ |
| PLGA | Hydrolytic | 6 | ~50 | PBS | Tissue engineering, drug carriers, and sensors | [ |
| PGA | 3 | 60 | ||||
| PCL/PLLA | Hydrolytic | 5 | 14 | NaOH solution | Bone tissue engineering | [ |
| Polyurethane copolymers | Hydrolytic | 8 | ∼10 | PBS | Soft tissue engineering | [ |
| PLA/thermoplastic | Hydrolytic | 4 | ∼10 | PBS | Medical and tissue engineering | [ |
The porosity and pore size of polymer scaffolds.
| Scaffold Material | Fabrication Method | Pore Size | Porosity (%) | Application | Ref. |
|---|---|---|---|---|---|
| Trabecular bone | NA | / | 50–90 | NA | [ |
| Cortical bone | / | 3–12 | |||
| Collagen | Freeze-drying | 150–250 | 98.8 ± 0.1 | Cartilage regeneration | [ |
| Collagen | Freeze-drying | / | 96.05 ± 0.11 | Bone tissue engineering | [ |
| Gelatin | Freeze-drying | ∼50–100 | ~98 | Cartilage cells | [ |
| Collagen/chitosan | Freeze-drying | 2–5 | 41.5% ± 2.69 | Tissue engineering | [ |
| Gelatin/chitosan | 5–10 | 81.02% ± 1.04 | |||
| Collagen/gelatin/chitosan | 10–20 | 61.34% ± 2.53 | |||
| Silk fibroin | Freeze-drying | 70 ± 23 | 92 | Tissue engineering | [ |
| Chitosan/gelatin | 280 ± 31 | 67 | |||
| Silk fibroin/chitosan/gelatin | 153 ± 18 | 80 | |||
| PCL | Electrospinning | ~44–64 | ~90 | ECM for tissue engineering | [ |
| PCL | Fused deposition modelling | / | 70 | Bone regeneration | [ |
| PCL | Extrusion | / | 49.0 ± 1.4 | Biomedical applications | [ |
| PCL/cellulose nanofibers | / | 49.5 ± 2.1 | |||
| Alginate | Freeze-drying | 250–320 | 85 ± 3.1 | Bone and cartilage tissue engineering | [ |
| Alginate dialdehyde–gelatin (ADA–GEL) | Freeze-drying | ~200 | ~90 | Bone tissue engineering | [ |
| PLA | Melt blending and hot pressing | 80.01 | 79.88 | Tissue engineering | [ |
| PPC | Gas foaming–salt leaching method | 418 ± 84 | 92.4 | Tissue engineering | [ |
| PGA | Electrospinning | 157.9 ± 30.5 | 91.5 ± 4.1 | Tissue-engineered intestines (TEI) | [ |
| PCL | 45.0 ± 12.6 | 67.9 ± 2.9 | |||
| PGA/PLLA | 84.7 ± 23.2 | 81.9 ± 3.3 | |||
| CollaTape | 54.4 ± 10.6 | 86.7 ± 3.4 | |||
| CollaTape/PLLA | 45.2 ± 22.5 | 76.6 ± 3.9 | |||
| Collagen/PLLA | Lyophilizing | 150–250 | >95 | Tissue engineering | [ |
Figure 5Scheme of different size scales of relevant structures.
Figure 6Schematic depicting the normal variation in elasticity of the indicated tissue.
Mechanical properties of scaffold materials.
| Scaffold Material | Scaffold Fabrication Method | Young’s Modulus | Strength (MPa) | Elongation (%) at Break | Scaffold Application | Ref. |
|---|---|---|---|---|---|---|
| Cortical bone | NA | 15–20 × 103 | 100–230 | / | NA | [ |
| Trabecular bone | 0.1–2 × 103 | 2–12 | / | |||
| Cancellous bone | 20–500 | 4–12 | / | |||
| Cartilage | 0.7–15.3 | 3.7–10.5 | / | |||
| Tendon | 0.143–2.31 × 103 | 24–112 | / | |||
| Silk fibroin (SF) | Solvent casting | 310 ± 90 | 22.8 ± 13.7 | 1.3 ± 0.3 | Soft tissue engineering | [ |
| Gelatin (G) | 370 ± 80 | 95.3 ± 25.6 | 5.3 ± 1.4 | |||
| SF/G (50/50) | 460 ± 70 | 89.4 ± 12.9 | 3.2 ± 0.6 | |||
| Collagen | Solution casting | / | 57 ± 6 | 16.3 ± 1.3 | Biomedical applications | [ |
| Collagen/cellulose nanofibers (8%) | 156 ± 5 | 23.06 ± 1.3 | ||||
| Alginate | Freeze-drying | 65 ± 13 ×10−3 | 326 ± 49 × 10−3 | / | Bone tissue engineering | [ |
| Alginate–gelatin–bioglass (5 w/v%) | 417 ± 33 × 10−3 | 908 ± 117 ×10−3 | ||||
| Silk fibroin | Freeze-drying | 70 ± 1.01 × 10−3 | 14 ± 2 × 10−3 | 27.5 ± 6.2 | Tissue engineering | [ |
| Chitosan/gelatin | 20 ± 1.3 × 10−3 | 5.6 ± 0.2 × 10−3 | 37.9 ± 3.8 | |||
| Silk fibroin/chitosan/gelatin | 27 ± 1.4 × 10−3 | 7.4 ± 0.3 × 10−3 | 36.6 ± 3.5 | |||
| Chitosan | Lyophilization | 6.8 ± 0.5 | 4.7 ± 0.4 | 62 ± 8.7 | Nerve regeneration, cartilage regeneration | [ |
| Chitosan/silk fibroin (7:3) | 5.3 ± 0.2 | 3.1 ± 0.7 | 56 ± 7.4 | |||
| Chitosan/silk fibroin (5:5) | 3.4 ± 0.3 | 2.1 ± 0.5 | 33 ± 4.8 | |||
| PCL | Cryogenic plotting/melt | 17.00 ± 0.75 | 1.71 ± 0.37 | / | Hard tissue regeneration | [ |
| Collagen | 0.55 ± 0.03 | 0.024 ± 0.003 | ||||
| Core (PCL)–shell (collagen/alginate) (shell–core = 0.18) | 8.68 ± 1.14 | 1.28 ± 0.17 | ||||
| PCL/gelatin/hyaluronic acid fibers | Electrospinning | / | 7.9 ± 0.8 | 69 | Glioblastoma extracellular matrix | [ |
| Gelatin | Electrospinning | 105 | 2.50 | 64 | Tissue engineering | [ |
| PCL | 4.98 | 2.70 | 126 | |||
| Gelatin/PCL | 30.8 | 1.29 | 138 | |||
| PLLA | Electrospinning | 55.93 ± 2.11 | 3.05 ± 0.21 | 37.3 ± 3.9 | Tissue engineering | [ |
| PLLA/PCL (90/10) | 18.11 ± 0.94 | 2.75 ± 0.09 | 66.5 ± 8.6 | |||
| PLLA/PCL (50/50) | 6.21 ± 0.64 | 1.58 ± 0.16 | 94.6 ± 7.5 | |||
| PGA | Melt compounding or lamination | 7000 | 115 | 16.4 | Biomedical applications | [ |
| PHB | Solution-cast | 3500 | 40 | 5 | Therapeutic applications | [ |
| Polypropylene | / | 1700 | 38 | 400 | Therapeutic applications | [ |
| Low-density polyethylene | / | 200 | 10 | 620 | Therapeutic applications | [ |
| Polystyrene | / | 3100 | 50 | / | Biomedical applications | [ |
| PVC | / | 300–2400 | 10–60 | 12–32 | Biomedical applications | [ |
| PLA | / | 2400 | 53 | 5 | Biomedical applications | [ |
| PCL | Electrospinning | 7.5 ± 0.7 | 1.5 ± 0.7 | 417 ± 58 | Vascular cells | [ |
| PCL/collagen (dry) | 3.8 ± 5.6 | 8.3 ± 1.2 | 62 ± 5 | |||
| PCL/collagen (wet) | 2.7 ± 1.2 | 4.0 ± 0.4 | 140 ± 13 | |||
| PLGA | / | 2000–4000 | 40–90 | < 10 | Biomedical applications | [ |
| PET | / | 3500 | 47 | 2–83 | Biomedical applications | [ |
| PA 6 | Melt compounding followed by injection moulding | 1947 ± 164 | 56 ± 1.0 | 70 | Biomedical applications | [ |
Commercial biopolymers for different biomedical applications.
| Polymer | Biomedical Application | Trade Name |
|---|---|---|
| Collagen | Provides an increased surface area for cell attachment, growth, and migration for tissue engineering applications | SpongeCol® |
| SphereCol® provides a 3D bio-scaffold which is optimal in many cell culture procedures | SphereCol® | |
| VitroCol® is especially ideal for human cell culture systems as a coating for surfaces, for providing preparations of thin layers of cultured cells, or for use as a solid gel. | VitroCol® | |
| Skin replacement product | TransCyte® | |
| Gelatin | A medical device intended for application to bleeding surfaces as a hemostatic | Gelfoam® |
| Silk | Therapeutic clothing | DermaSilk® |
| Chitosan | Natural wound care for animals—big and small | ChitoClear® |
| Natural healing and scar recovery | ChitoCare® | |
| Hyaluronic acid | Cell culture scaffolds | HyStem™ |
| PGA | Mainly applied for absorbable sutures and also for stents, adhesion barriers, absorbable reinforcement for artificial dura, and scaffolds | BioDegmer® PGA |
| The first biodegradable synthetic suture (1969) | DEXON | |
| Bone internal fixation devices | Biofix® | |
| Medical device applications | PURASORB® PG | |
| Absorbable mesh for temporary wound and organ support | Safil® Mesh | |
| PLA | Meniscus repair fixation devices | The Meniscus Arrow (Bionx Implants, Inc., Blue Bell, PA), |
| Fixed installations such as bone plates, bone screws, surgical | Revode 100 series | |
| PGLA (Poly(glycolide-co-L-lactide)) | Mainly applied for absorbable sutures and also for stents, scaffolds, adhesion barriers, artificial dura, and guided tissue regeneration (GTR) membranes | BioDegmer® PGLA |
| A temporary wound or organ support | VICRYL™ (polyglactin 910) Woven Mesh | |
| PGDLLA | Mainly applied for GTR membranes (porous membranes) for regeneration and adhesion of lost periodontal supporting tissues caused by periodontal disease | BioDegmer® PGDLLA |
| PLLA | Mainly applied for absorbable bone fixture and utilized for stents, scaffolds, and adhesion barriers | BioDegmer® PLLA |
| Orthopedic fixation devices | Bio-Anchor® | |
| Medical device applications | PURASORB® PL grades | |
| Fabrication of medical research devices and tissue engineering research solutions, such as orthopedic or soft tissue fixation devices. | Resomer® series | |
| PDLA | Bone fixture material | BioDegmer® PDLA |
| Medical device applications | PURASORB® PD grades | |
| PDLLA | Mainly applied for the coating of suture | BioDegmer® PDLLA |
| Medical device applications | PURASORB® PDL grades | |
| Form scaffolds make it a useful biomaterial in biomedical and tissue engineering | Resomer® R 207 S | |
| PCL | Medical device applications | PURASORB® PC |
| 67% PGA: 33% trimethylene carbonate (TMC) | Soft tissue reinforcement | BIO-A® |
Figure 7Conventional and advanced scaffold fabrication techniques.
Biopolymer scaffold fabrication techniques.
| Fabrication Method | Advantages | Disadvantages | Materials | Ref. |
|---|---|---|---|---|
|
Control over porosity, pore size, and crystallinity. Highly porous materials with interconnected pores. Simple and reproducible technique. |
Limited mechanical properties, residual solvents, and porogen material. Longer processing time. This technique is mainly applied to produce thin membranes. | Different classes of synthetic polymers (e.g., PLLA, PLGA, or PEG) and natural polymers | [ | |
|
Independent control over porosity, pore size, pore interconnectivity, and geometry. |
The requirement of high temperature for the non-amorphous polymer. Requires a residual porogen. Longer processing time. Limited mechanical properties. Expensive technique. | PLA, PGA, PLGA–gelatin, PA | [ | |
|
Free of harsh organic solvents. Control over porosity and pore size. Minimum loss of bioactive molecules. No need for the leaching process. High porosity > 90%. |
Limited mechanical properties, inadequate pore interconnectivity. Longer processing time. | PLA, PLLA, or PLGA | [ | |
|
High temperature and a separate leaching step not required. Highly porous materials, with random or oriented pores. |
Pore size is relatively small and porosity is often irregular. Long processing time. Expensive technique. | Natural polymers like alginate, agarose, gelatin, chitosan, etc., and PGA, PLLA, PLGA, PLGA/PPF blends | [ | |
|
Control over porosity, pore size, and fiber diameter. High surface area. Cheap and simple. |
Limited mechanical properties, pore size decreases with fiber thickness. Not applicable for all polymers. Not sufficient for cell seeding. Not sufficient for cell infiltration. | Synthetic polymers (PEO, PLGA, PLLA, PCL, PVA) and natural polymers (collagen, silk fibroin, elastin, fibrinogen, chitosan) and their composites | [ | |
|
Creates 3D scaffolds for tissue engineering with complex geometries. Pores of multiple sizes, which can ensure a selective transport of cells versus smaller molecules. |
The time required for fabrication increases cubically as resolution increases. | PPF, PEO, PEG | [ | |
|
Highly capable of producing objects with intricate structures and shapes containing channels, overhanging features, and gradient structures. TE scaffolds with controlled porosity and customized architecture. |
Incapability to use polymers in the hydrogel form. Impossibility to encapsulate cells in scaffolds. Limitation in forming sharp corners and clear boundaries, making it impossible to create small details. | Nondegradable or degradable biopolymers (e.g., PE, PCL, PLLA, PLGA, etc.), and composites can be processed into scaffolds for TE | [ | |
|
3D models of custom-made implants cast for individual patients. FDM processes can achieve pore sizes ranging from 160 to 700 microns, with porosities ranging from 48% to 77%. |
Pore anisotropy and the geometry of pore connectivity are substantially limited due to the continuous deposition process. FDM is typically limited to synthetic thermoplastic polymers, thereby eliminating many natural biomaterials and thermoset synthetic polymers. | Biodegradable materials used for this method include PCL, PLGA, polycarbonate, polypropylene, and various polyesters | [ | |
|
Able to create almost any shape or geometric feature, allows defined internal architectures for implants. |
The addition of a chemical binder. Post-fabrication efforts to remove the residual solvent such as vacuum drying are not completely effective; therefore, the issue of cytotoxicity in 3D printing (3DP)-fabricated scaffolds remains. | PEO, PCL, | [ | |
|
Biomimicry. Autonomous self-assembly. Small tissue building blocks. |
The development of biomaterials for 3D bioprinting is still in its early stages. | Common biomaterials | [ |